TYVASO® (treprostinil) Inhalation Solution and TYVASO DPI® (treprostinil) Inhalation Powder

TYVASO describes itself simply: "TYVASO and TYVASO DPI are approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO." To AI engines like ChatGPT and Perplexity it is partially visible, scoring 6.1 out of 10, readable in places and missing in others.

On the page itself the strengths are clear: a clear heading structure, crawler access and the files AI engines look for and sitemaps and entity links AI can follow. It is passable on a partly stated business identity. What holds it back is structured data describing the business and credibility markers like credentials or reviews.

Away from its own site, other sites link to it. There is some, but not much, sign that the domain is only lightly established. Beyond that, AI engines do not yet recognise it as a distinct business, there is no press coverage to draw on, nobody is discussing it where AI engines look and it does not come up on Reddit. Those are earned elsewhere on the web, not fixed on the site itself.

AI crawlers have visited once in our tracking, including ClaudeBot (Anthropic). It does link out to several social profiles, which helps engines tie the brand together.